Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876510 · ClinicalTrials.gov registry record · Phase 1
ACTolog in Patients With Solid Cancers
A Phase 1 study, sponsored by Immatics US.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT02876510 is a Phase 1 study that has completed, run by Immatics US. The registered enrollment target is 38 participants.
The verdict
NCT02876510, a Phase 1 study, has completed, sponsored by Immatics US.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL IMA101 product
- BIOLOGICAL Recombinant human interleukin-2
- DIAGNOSTIC_TEST IMADetect
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2017-06-30 |
| Est. Completion | 2021-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02876510
The ClinicalTrials.gov registry entry for NCT02876510 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02876510 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02876510 about?
NCT02876510 is a clinical study titled "ACTolog in Patients With Solid Cancers". The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
What is the current status of trial NCT02876510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2017-06-30. Estimated completion is 2021-09-22.
What interventions are being tested in trial NCT02876510?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), IMA101 product (BIOLOGICAL), Recombinant human interleukin-2 (BIOLOGICAL), IMADetect (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02876510?
This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.